Core Insights - Integra LifeSciences Holdings Corporation reported a total revenue of $402.1 million for Q3 2025, reflecting a 5.6% increase on a reported basis and a 5.0% increase on an organic basis compared to the previous year [4][8][29] - The company experienced a GAAP net loss of $(5.4) million, or $(0.07) per diluted share, an improvement from a net loss of $(10.7) million, or $(0.14) per diluted share, in Q3 2024 [5][28] - Adjusted net income for Q3 2025 was $41.6 million, or $0.54 per diluted share, compared to $31.7 million, or $0.41 per diluted share, in the prior year [5][39] Financial Performance - Total reported revenues of $402.1 million increased by 5.6% year-over-year, with a GAAP gross margin of 51.5%, down from 52.6% in Q3 2024 [4][28] - Adjusted EBITDA for Q3 2025 was $78.5 million, representing 19.5% of revenue, compared to $61.8 million, or 16.2% of revenue, in the prior year [4][36] - The company generated cash flow from operations of $40.9 million in the quarter, with total balance sheet debt at $1.8 billion and net debt at $1.6 billion [10][11] Segment Performance - Codman Specialty Surgical, which accounts for approximately 70% of revenues, reported total revenues of $292.6 million, showing reported growth of 8.1% and organic growth of 7.1% compared to Q3 2024 [6][29] - Tissue Technologies, representing about 30% of revenues, saw total revenues of $109.5 million, reflecting a reported decline of 0.5% and an organic decline of 0.3% compared to the previous year [10][29] 2025 Outlook - For Q4 2025, the company expects reported revenues in the range of $420 million to $440 million, indicating a reported growth of (5.1%) to (0.6%) and organic growth of (5.9%) to (1.4%) [12][13] - The full-year 2025 revenue guidance has been updated to a range of $1.620 billion to $1.640 billion, representing reported growth of 0.6% to 1.8% and organic growth of (1.6%) to (0.4%) [13] Strategic Initiatives - The company is implementing a comprehensive plan to strengthen its supply chain and quality management system, aiming to improve overall performance and drive transformation [3][15] - The relaunch of PriMatrix® and Durepair® was completed ahead of schedule through a dual sourcing supply strategy [8][15]